Breaking News Instant updates and real-time market news.

NBEV

New Age Beverages

$5.94

-0.07 (-1.16%)

, CGC

Canopy Growth

$47.15

-0.71 (-1.48%)

08:45
10/12/18
10/12
08:45
10/12/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: New Age Beverages (NBEV) 36.61% +0.32, Canopy Growth (CGC) 6.58% +0.24, Trevena (TRVN) 2.84% +0.13, Amarin (AMRN) 3.39% +0.08, Shire (SHPG) 0.90% +0.07, Vital Therapies (VTL) 35.99% +0.07, Century Aluminum (CENX) 0.92% +0.07, Paratek Pharmaceuticals (PRTK) 3.21% +0.06, MannKind (MNKD) 10.25% +0.06, and Government Properties (GOV) 1.31% +0.06.

NBEV

New Age Beverages

$5.94

-0.07 (-1.16%)

CGC

Canopy Growth

$47.15

-0.71 (-1.48%)

TRVN

Trevena

$0.94

(0.00%)

AMRN

Amarin

$19.31

1.98 (11.43%)

SHPG

Shire

$168.23

-3.23 (-1.88%)

VTL

Vital Therapies

$0.33

0.005 (1.54%)

CENX

Century Aluminum

$10.09

-0.1 (-0.98%)

PRTK

Paratek Pharmaceuticals

$8.91

-0.39 (-4.19%)

MNKD

MannKind

$1.51

-0.17 (-10.12%)

GOV

Government Properties

$10.20

-0.38 (-3.59%)

  • 13

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 01

    Nov

  • 02

    Nov

  • 21

    Dec

NBEV New Age Beverages
$5.94

-0.07 (-1.16%)

09/21/18
09/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bluebird Bio (BLUE) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Salveen Richter saying rating change is is not driven by concerns around Bluebird's pipeline execution or emerging competitive threats. The analyst just believes appreciation of key aspects of his investment thesis are better reflected in the shares at current valuation levels. 2. Venator Materials (VNTR) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas saying he believes lower prices and higher raw material costs for TiO2, coupled with higher capital expenditures, diminishes Venator's free cash flow outlook. 3. Antero Resources (AR) downgraded to Market Perform from Outperform at BMO Capital with analyst Phillip Jungwirth citing valuation. 4. New Age Beverages (NBEV) downgraded to Hold from Buy at Maxim. 5. Rowan Companies (RDC) downgraded to Hold from Buy at HSBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/18
MAXM
09/21/18
DOWNGRADE
MAXM
Hold
New Age Beverages downgraded to Hold from Buy at Maxim
09/18/18
NORL
09/18/18
NO CHANGE
NORL
New Age Beverages to debut CBD line at NACS, says Northland
Northland spoke with New Age Beverages management who said they would debut a CBD line at the North American Convenience Show, or NACS, The company has been testing a CBD beverage in Colorado for the last 8 months, gaining insight from consumer communication, and product formulation, and believes it has a lead on the right dosage as well as shelf-life.
09/04/18
NORL
09/04/18
INITIATION
Target $3
NORL
Outperform
New Age Beverages initiated with an Outperform at Northland
Northland initiated New Age Beverages with an Outperform and $3 price target.
CGC Canopy Growth
$47.15

-0.71 (-1.48%)

10/05/18
MSCO
10/05/18
NO CHANGE
Target $255
MSCO
Overweight
Constellation Brands price target raised to $255 from $251 at Morgan Stanley
Morgan Stanley analyst Dara Mohsenian believes Constellation Brands' (STZ) strong beer fundamentals in Q2 should blunt some investor concerns and continues to think that the market is not appropriately valuing the company's strong long-term growth prospects in beer. The analyst, who also views negative sentiment around the company's investment in cannabis company Canopy Growth (CGC) as overblown, keeps an Overweight rating on Constellation and raised his price target to $255 from $251.
10/09/18
COWN
10/09/18
NO CHANGE
Target $172
COWN
Outperform
Tilray price target raised to $172 from $62 at Cowen
Cowen analyst Vivien Azer raised her price target for Tilray (TLRY) to $172 from $62 and keeps an Outperform rating on the shares. The analyst also raised her price target for Outperform-rated Canopy Growth (CGC) to C$82 from C$74.
10/05/18
PIVT
10/05/18
NO CHANGE
Target $300
PIVT
Buy
Constellation Brands price target raised to $300 from $265 at Pivotal Research
Pivotal Research analyst Timothy Ramsey said Constellation Brands reported a "beautiful quarter" and that its core business is "growing faster than anyone believed." In terms of its investment in Canopy Growth (CGC), Ramsey said that is "very likely a masterstroke." He raised his estimates for Constellation on the heels of the report, increased his price target to $300 and keeps a Buy rating on the shares.
10/04/18
JPMS
10/04/18
NO CHANGE
Target $250
JPMS
Overweight
JPMorgan sees opportunity to buy Constellation Brands shares after earnings
JPMorgan analyst Andrea Teixeira said that Constellation Brands' (STZ) better than expected Q2 EPS was driven by stronger top-line growth, better operating profit growth and a favorable tax rate. The company's updated FY19 EPS view of $9.60-$9.75, when adjusted for 25c-30c dilution from its increased investment in Canopy Growth (CGC), compares to Teixeira's $9.26 estimate heading into the quarter and the consensus forecast of $9.30, she noted. The analyst, who sees an opportunity to buy Constellation shares following the report, keeps an Overweight rating on the stock, which is up nearly 5% to $220.65 in afternoon trading.
TRVN Trevena
$0.94

(0.00%)

10/12/18
JMPS
10/12/18
NO CHANGE
Target $4
JMPS
Outperform
Trevena price target lowered to $4 from $15 at JMP Securities
JMP Securities analyst Jason Butler said the mixed Advisory Committee vote on Trevena's application for oliceridine is likely to result in an approval delay, but he has not given up on the potential for issues raised by the panel to be addressed with label modifications and post-marketing studies. He now assume the company receiving a CRL as his base case scenario, which would result in an 18-month delay to approval. Butler, who cut his probability of approval for oliceridine to 70% from 90% and lowered his peak sales estimate, reduced his price target on Trevena shares to $4 from $15 but keeps an Outperform rating on the stock.
10/12/18
NEED
10/12/18
DOWNGRADE
NEED
Hold
Trevena downgraded to Hold at Needham on oliceridine recommendation
As reported earlier, Needham analyst Alan Carr downgraded Trevena to Hold after the FDA's Administration Anesthetic and Analgesic Drug Products Advisory Committee, or AADPAC, voted 7-8 against the approval of oliceridine use in acute pain management. The analyst notes that documents from the FDA released this week also showed some reluctance in the drug's overall profile, and combined with this latest AADPAC decision, render the approval of oliceridine as improbable. Carr adds that Trevena will likely face challenges obtaining financial resources to support commercial launch even if oliceridine was approved next month, noting that he now awaits the official FDA decision and discussion of development for Trevena's other pipeline programs.
10/10/18
JEFF
10/10/18
DOWNGRADE
Target $1
JEFF
Hold
Trevena downgraded to Hold from Buy at Jefferies
Jefferies analyst Biren Amin downgraded Trevena to Hold and cut his price target for the shares to $1 from $10. The FDA has an unfavorable view on both efficacy and safety profile of the company's oliceridine versus morphine, Amin tells investors in a research following yesterday's briefing documents. More critically, the documents make clear that Trevena failed to heed critical FDA advice in its Phase III trial design, the analyst adds. He sees no clear path forward for oliceridine.
10/12/18
NEED
10/12/18
DOWNGRADE
NEED
Hold
Trevena downgraded to Hold from Buy at Needham
AMRN Amarin
$19.31

1.98 (11.43%)

10/04/18
CANT
10/04/18
NO CHANGE
Target $35
CANT
Overweight
Amarin price target raised to $35 from $15 at Cantor Fitzgerald
09/26/18
JMPS
09/26/18
NO CHANGE
Target $300
JMPS
Outperform
JMP Securities 'optimistic' on Madrigal following Amarin's Vascepa data
JMP Securities analyst Liisa Bayko said she feels "optimistic" regarding MGL-3196's potential cardiovascular benefit following Amarin's (AMRN) announcement that Vascepa reduced the risk of major adverse CV events in the REDUCE-IT long-term outcomes study. The REDUCE-IT data lays an argument that Madrigal's MGL-3196, which has a similar impact on cardiometabolic parameters, may also provide a CV benefit, contends Bayko. She maintains an Outperform rating and $300 price target on Madrigal Pharmaceuticals shares.
09/26/18
CANT
09/26/18
NO CHANGE
Target $15
CANT
Overweight
Cantor says concerns over Amarin IP 'making a mountain out of a molehill'
After speaking with the company and reviewing the public record of its patents and abbreviated new drug application-related matter, Cantor Fitzgerald analyst Louise Chen believes concerns over Amarin's intellectual property are "making a mountain out of a molehill." Vascepa's intellectual property will keep out generics until August 2029, Chen tells investors in a research note. She sees peak sales potential of "billions of dollars" and reiterates an Overweight rating on Amarin with a $15 price target.
09/25/18
JEFF
09/25/18
NO CHANGE
Target $15
JEFF
Buy
Jefferies boosts Amarin target to $15, sees 'meaningful potential' for buyout
Jefferies analyst Roger Song raised his price target for Amarin to $15 saying the 25% MACE reduction in the REDUCE-IT "clearly gives" the company an opportunity to grow sales to $2B-$3B. His model now assumes peak adjusted sales of $3B and he keeps a Buy rating on Amarin. Song thinks the shares "have room to climb higher" after yesterday's 300% rally. The analyst also sees "meaningful potential" for a takeover event since Amarin is now "significantly de-risked."
SHPG Shire
$168.23

-3.23 (-1.88%)

09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
09/04/18
BERN
09/04/18
DOWNGRADE
BERN
Market Perform
Shire downgraded to Market Perform from Outperform at Bernstein
VTL Vital Therapies
$0.33

0.005 (1.54%)

08/21/18
08/21/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Conagra Brands (CAG) initiated with an Overweight at Stephens. 2. Vital Therapies (VTL) initiated with an Overweight at Cantor Fitzgerald. 3. Jefferies Financial Group (JEF) initiated with an Outperform at Keefe Bruyette. 4. Madison Square Garden (MSG) and MSG Networks (MSGN) were initiated with an Outperform at Imperial Capital. 5. Berry Petroleum (BRY) initiated with a Buy at Johnson Rice and Tudor Pickering. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/18
RAJA
09/12/18
DOWNGRADE
RAJA
Market Perform
Vital Therapies downgraded to Market Perform from Outperform at Raymond James
09/12/18
WBLR
09/12/18
DOWNGRADE
WBLR
Market Perform
Vital Therapies downgraded to Market Perform from Outperform at William Blair
William Blair analyst Katherine Xu downgraded Vital Therapies to Market Perform following this morning's failed study. The stock in premarket trading is down 89%, or $5.60, to 70c.
08/21/18
CANT
08/21/18
INITIATION
Target $18
CANT
Overweight
Vital Therapies initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner initiated Vital Therapeutics with an Overweight rating and $18 price target. In a research note to investors, Tanner says he believes the ongoing VTL-308 Phase trial of the extracorporeal liver assist device in patients with several alcoholic hepatitis has been de-risked through incorporation of learnings from the previous VTI-208 trial, adding that he believes commercialization requirements are of a scale that Vital could undertake without a partner, if approved. Additionally, Tanner contends that pricing corresponding with the unmet medical need and clinical sequelae of untrated sAH could create significant value for investors.
CENX Century Aluminum
$10.09

-0.1 (-0.98%)

10/02/18
DBAB
10/02/18
DOWNGRADE
Target $15
DBAB
Hold
Century Aluminum downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Century Aluminum to Hold and lowered his price target for the shares to $15 from $20. The analyst sees growing risks and reduced upside potential at current share levels.
10/02/18
10/02/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GE UPGRADED AT RBC, WOLFE: RBC Capital analyst Deane Dray upgraded General Electric (GE) to Outperform from Sector Perform and raised his price target for the shares to $15 from $13. The analyst believes a floor has been put in the shares following news of Larry Culp being named Chairman and CEO. Additionally, GE was upgraded to Outperform from Peer Perform at Wolfe Research. DEUTSCHE SEES HEIGHTENED RISKS TO FACEBOOK ESTIMATES: After attending the first day of AdWeek, Deutsche Bank analyst Lloyd Walmsley sees heightened risk to the Q3, Q4 and 2019 consensus estimates for Facebook (FB). The analyst said he's starting to hear more cautious feedback and that Facebook seems on the defensive, particularly following last week's data breach disclosure. Walmsley, however, continues to view Facebook as attractively valued and kept a Buy rating on the shares with a $205 price target. JPMORGAN ADDS WEIGHT WATCHERS TO FOCUS LIST: JPMorgan analyst Christina Brathwaite added Weight Watchers (WTW) to her firm's America's Analyst Focus while keeping an Overweight rating on the shares with a $120 price target. The stock's 30% pullback from its peak on June 20 presents a "compelling entry point for investors who missed the stock's appreciation the first time around," Brathwaite said. Despite the post-earnings selloff, the analyst believes the Q2 print was actually indicative that Weight Watchers' growth story remains on track. Further, she believes the changes announced last week, including its new rewards program, as well as the company's Invite a Friend program, will help drive member recruitment and retention going forward. AMBEV DOUBLE DOWNGRADED BY UBS: UBS analyst Alan Alanis double downgraded Ambev (ABEV) to Sell from Buy and lowered his price target for the shares to R$17 from R$23. AmBev trades at a 25% higher valuation than parent company AB InBev (BUD), which is unwarranted, Alanis believes. He believes Ambev shares at current levels are more than pricing in the company's favorable outlook. Further, he expects consensus estimates to come down due to a tougher competitive environment, a "tepid" Brazilian economic recovery and currency headwinds. DEUTSCHE DOWNGRADES METAL STOCKS: Deutsche Bank analyst Jeremy Kliewer downgraded Century Aluminum to Hold from Buy and lowered his price target for the shares to $15 from $20, stating that Century's margins could remain pressured for longer due to alumina supply disruptions. Meanwhile, Deutsche's Chris Terry downgraded Reliance Steel (RS) to Hold from Buy and lowered his price target for the shares to $90 from $100, and downgraded U.S. Steel (X) to Hold from Buy and lowered his price target for the shares to $35 from $47. The analyst said his view on the steel sector is "moderating post peak pricing." Most positive data points and catalysts have now largely played out, Terry believes.
10/02/18
DBAB
10/02/18
DOWNGRADE
Target $15
DBAB
Hold
Deutsche downgrades Century Aluminum on growing risks, reduced upside
Deutsche Bank analyst Jeremy Kliewer downgraded Century Aluminum to Hold from Buy and lowered his price target for the shares to $15 from $20. Century's margins could remain pressured for longer due to alumina supply disruptions, Kliewer tells investors in a research note. Further, the analyst feels little progress has been made with Santee Cooper, the electrical supplier at the company's Mt. Holly smelter, and that support for import tariffs may decline further following the November mid-term elections. As such, the analyst sees reduced upside potential and growing risk for Century Aluminum shares.
10/04/18
RILY
10/04/18
NO CHANGE
Target $20
RILY
Buy
Century Aluminum price target lowered to $20 from $23 at B. Riley FBR
B. Riley FBR analyst Lucas Pipes lowered his price target for Century Aluminum to $20 after adjusting his estimates for the company and Aloca (AA) to reflect expected Q3 price realizations and his firm's upgraded long-term price deck. The analyst keeps a Buy rating on the shares.
PRTK Paratek Pharmaceuticals
$8.91

-0.39 (-4.19%)

08/06/18
HCWC
08/06/18
NO CHANGE
Target $55
HCWC
Buy
Paratek risk/reward favorable into Wednesday's panel, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce believes the risk/reward for Paratek Pharmaceuticals is "positively-skewed" into Wednesday's FDA panel meeting for omadacycline. The analyst expects a "relatively smooth" panel and would be buyers of the stock heading into the early October FDA action date. Arce keeps a Buy rating on Paratek with a $55 price target.
08/27/18
BOFA
08/27/18
INITIATION
Target $13
BOFA
Neutral
Paratek Pharmaceuticals initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Paratek Pharmaceuticals with a Neutral and $13 price target.
08/09/18
WEDB
08/09/18
NO CHANGE
Target $20
WEDB
Tone of Paratek advisory committee meeting 'extremely positive,' says Wedbush
Wedbush analyst Robert Driscoll said the tone of yesterday's antimicrobials drug advisory committee meeting was "extremely positive" regarding to the data presented by Paratek and he expects full approval of omadacycline for the treatment of both acute bacterial skin infections and community-acquired bacterial pneumonia in early October. He believes the flexible dosing, low risk of C. difficile and lack of drug-drug interactions will support significant commercial success of omadacycline. Driscoll keeps an Outperform rating and $20 price target on Paratek shares.
08/08/18
RAJA
08/08/18
NO CHANGE
RAJA
Outperform
AdCom vote increases chances of Paratek's omadacycline approval, says Raymond James
Raymond James analyst Laura Chico notes that the FDA's Advisory Committee voted 17-1 in favor of approval for Paratek Pharmaceuticals' omadacycline in skin infections and 14-4 in favor of approval in pneumonia. While the analyst acknowledges that the FDA is not bound by the committee's decision, they nearly always follow the recommendation. Thus, she thinks the vote incrementally increases the chances for an omadacycline approval. Chico reiterates an Outperform rating on the shares.
MNKD MannKind
$1.51

-0.17 (-10.12%)

06/07/18
HCWC
06/07/18
NO CHANGE
Target $5
HCWC
Buy
MannKind's treprostinil could be 'transformational asset,' says H.C. Wainwright
MannKind's (MNKD) announcement this morning of a successful Phase 1 completion of its Technosphere treprostinil dry powder inhalation for pulmonary arterial hypertension comes months ahead of schedule, H.C. Wainwright analyst Oren Livnat tells investors in a research note. The news is an important reminder that MannKind's inhalation drug delivery platforms offer potentially much more value than just Afrezza inhalable insulin, the analyst contends. He believes inhalable treprostinil, which is not yet in his model, could "ultimately prove a transformational asset." Livnat points out that United Therapeutics' (UTHR) pulmonary arterial hypertension treprostinil franchise is estimated to deliver over $1.1B of sales in 2018. The analyst keeps a Buy rating on MannKind with a $5 price target.
09/05/18
HCWC
09/05/18
NO CHANGE
Target $4
HCWC
Buy
MannKind valuation 'floor' raised with United deal, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says United Therapeutics (UTHR) is the "ideal partner" for MannKind (MNKD) to develop and commercialize technosphere treprostinil dry powder inhalation for pulmonary arterial hypertension. The deal announced yesterday represents additional validation of MannKind's "underappreciated" DPI and delivery platforms beyond Afrezza, Livnat tells investors in a research note. Importantly, the deal brings in non-dilutive financing, "raises the floor" on MannKind's valuation, and "offers a new path to potential long-term upside from here even if Afrezza never reaches the potential we think it deserves," Livnat writes. The analyst reiterates a Buy rating on MannKind shares with a $4 price target. The stock closed yesterday up 89%, or 98c, to $2.08.
06/26/18
HCWC
06/26/18
NO CHANGE
Target $5
HCWC
Buy
MannKind gained 'new credibility' for Afrezza at ADA, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said MannKind materially increased Afrezza's relevance and gained "new credibility" with multiple data presentations, including a well-attended symposium and oral presentation, at the American Diabetes Association meeting that was just held. He called the event an "eye-opening experience" that showed Afrezza's defining differentiation is not that it is inhalable, but that it "really is the best meal-time insulin, full stop." Following the ADA event, Livnat reiterated his Buy rating and $5 target on MannKind shares.
08/03/18
HCWC
08/03/18
NO CHANGE
Target $4
HCWC
Buy
MannKind price target lowered to $4 from $5 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for MannKind to $4 citing the company's "light" Q2 results. The analyst, however, still models for an Afrezza ramp in the second half of the year. He remains remain "very bullish long-term if the product can be resourced" and keeps a Buy rating on MannKind.
GOV Government Properties
$10.20

-0.38 (-3.59%)

09/17/18
JMPS
09/17/18
DOWNGRADE
JMPS
Market Perform
Select Income REIT downgraded to Market Perform at JMP Securities
JMP Securities analyst Mitchell Germain downgraded Select Income REIT (SIR) to Market Perform from Outperform following the announcement of its agreement to merge with Government Properties Income Trust (GOV).
04/16/18
MSCO
04/16/18
NO CHANGE
Target $13
MSCO
Underweight
Government Properties price target lowered to $13 at Morgan Stanley
Morgan Stanley analyst Vikram Malhotra lowered his price target on Government Properties to $13 and also reduced his FY18 FFO target to $2.03 from $2.10, citing tenant move-out trends and asset sales as the headwinds over the near term. The analyst also keeps his Underweight rating on Government Properties, adding that the diminished performance is putting the REITs dividend at risk.
09/19/18
MSCO
09/19/18
UPGRADE
MSCO
Equal Weight
Morgan Stanley upgrades Select Income to Equal Weight after deal announcement
As previously reported, Morgan Stanley analyst Vikram Malhotra upgraded Select Income REIT (SIR) to Equal Weight from Underweight citing the announcement of its plans to merge with Government Properties Income Trust (GOV) to create a REIT focused on owning and operating office buildings primarily leased to single tenants, including government entities. The deal also aims to reduce the complicated ownership structure between Government Properties, Select Income and Industrial Logistics Property Trust (ILPT), Malhotra noted. While he raised his price target on Select Income to $24, he lowered his price target on Government Properties to $11.50 from $13 and keeps an Underweight rating on its shares. The analyst continues to see ongoing risks to growth, driven by lower renewal rates and limited pricing power, and risks to its debt reduction plans, noting that the company intends to sell over $1B in assets during the next 6-9 months to reduce leverage.

TODAY'S FREE FLY STORIES

NYT

New York Times

$32.02

0.06 (0.19%)

12:25
02/20/19
02/20
12:25
02/20/19
12:25
Hot Stocks
New York Times publisher responds to Trump's 'enemy of the people' tweet »

After President Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

RTTR

Ritter Pharmaceuticals

$0.66

-0.0104 (-1.55%)

12:25
02/20/19
02/20
12:25
02/20/19
12:25
Conference/Events
Ritter Pharmaceuticals to host conference call »

Expert call with Dr Chey,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

ZNGA

Zynga

$5.09

-0.01 (-0.20%)

12:20
02/20/19
02/20
12:20
02/20/19
12:20
Options
Defensive option play in Zynga as shares ease off 52-week highs »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 11

    Mar

HSY

Hershey

$109.97

0.275 (0.25%)

12:19
02/20/19
02/20
12:19
02/20/19
12:19
Earnings
Hershey issues long-term adjusted EPS growth target of 6%-8% »

Hershey in conference…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

MCS

Marcus

$40.59

1 (2.53%)

12:18
02/20/19
02/20
12:18
02/20/19
12:18
Hot Stocks
Marcus raises quarterly dividend 6.7% to 16c per share »

Directors of The Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 02

    Apr

  • 02

    Apr

  • 06

    Jun

HSY

Hershey

$109.95

0.255 (0.23%)

12:18
02/20/19
02/20
12:18
02/20/19
12:18
Hot Stocks
Hershey would consider debt to EBITDA ratio over 2.0 times for acquisition »

Hershey in conference…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
02/20/19
02/20
12:17
02/20/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
02/20/19
02/20
12:16
02/20/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
02/20/19
02/20
12:15
02/20/19
12:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

CVS

CVS Health

$64.92

-5 (-7.15%)

, TSLA

Tesla

$302.25

-3.31 (-1.08%)

12:11
02/20/19
02/20
12:11
02/20/19
12:11
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks opened little…

CVS

CVS Health

$64.92

-5 (-7.15%)

TSLA

Tesla

$302.25

-3.31 (-1.08%)

BMY

Bristol-Myers

$51.21

-0.14 (-0.27%)

CELG

Celgene

$91.25

0.54 (0.60%)

KNDI

Kandi Technologies

$8.45

2.52 (42.50%)

GRMN

Garmin

$82.11

11.145 (15.71%)

NVTA

Invitae

$18.55

2.06 (12.49%)

OMI

Owens & Minor

$6.48

-1.46 (-18.39%)

WIX

Wix.com

$110.43

-15.275 (-12.15%)

CXO

Concho Resources

$114.44

-6.51 (-5.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 12

    Mar

  • 18

    Mar

  • 18

    Mar

  • 19

    Mar

  • 18

    May

  • 20

    May

  • 22

    May

  • 28

    May

HSY

Hershey

$110.01

0.315 (0.29%)

12:09
02/20/19
02/20
12:09
02/20/19
12:09
Hot Stocks
Hershey reaffirms 2019 guidance at CAGNY Conference »

Hershey said that in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

KNX

Knight-Swift

$34.96

0.73 (2.13%)

12:05
02/20/19
02/20
12:05
02/20/19
12:05
Options
Knight Transportation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

12:05
02/20/19
02/20
12:05
02/20/19
12:05
General news
U.S. corporate bond update: the calendar remains active. »

U.S. corporate bond…

DNLI

Denali Therapeutics

$21.44

-0.16 (-0.74%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Denali granted orphan status for mucopolysaccharidosis treatment »

The FDA granted Denali…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDY

Dr. Reddy's

$35.97

-0.45 (-1.24%)

12:03
02/20/19
02/20
12:03
02/20/19
12:03
Hot Stocks
Dr. Reddy's announces re-launch of buprenorphine, naloxone sublingual film »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

HSY

Hershey

$109.86

0.165 (0.15%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Earnings
Hershey backs FY19 adjusted EPS growth view of 5%-7%, consensus $5.64 »

Backs FY19 net sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

QTT

Qutoutiao

$12.66

0.25 (2.01%)

12:01
02/20/19
02/20
12:01
02/20/19
12:01
Downgrade
Qutoutiao rating change  »

Qutoutiao downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

BHC

Bausch Health

$23.23

-1.94 (-7.71%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Bausch Health falls -7.7% »

Bausch Health is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 12

    Mar

  • 12

    Mar

IDT

IDT Corp

$6.48

-0.68 (-9.50%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
IDT Corp falls -9.1% »

IDT Corp is down -9.1%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.62

-1.32 (-16.62%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Owens & Minor falls -16.6% »

Owens & Minor is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

I

Intelsat

$24.38

2.755 (12.74%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Intelsat rises 12.8% »

Intelsat is up 12.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 11

    Mar

  • 11

    Mar

QUAD

Quad/Graphics

$16.58

2.04 (14.03%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
Quad/Graphics rises 14.4% »

Quad/Graphics is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

LKSD

LSC Communications

$9.47

1.18 (14.23%)

12:00
02/20/19
02/20
12:00
02/20/19
12:00
Hot Stocks
LSC Communications rises 14.6% »

LSC Communications is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLNE

Clean Energy

$2.23

0.24 (12.06%)

11:58
02/20/19
02/20
11:58
02/20/19
11:58
Hot Stocks
Clean Energy jumps 12% after seeing demand increases for RNG from refuse sector »

Clean Energy Fuels,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

  • 12

    Mar

TKC

Turkcell

$6.97

0.06 (0.87%)

11:56
02/20/19
02/20
11:56
02/20/19
11:56
Hot Stocks
Breaking Hot Stocks news story on Turkcell 

Turkcell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 14

    Mar

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.